IDEXX’s Innovation Engine Powers Through Soft Vet Visits with an 1,100bps Premium

Q2 beat with CAG Dx recurring +10.3% organically, raised full-year guidance, and inVue FNA rollout accelerates.

IDXX · Earnings Call · 2026-08-04

Innovation Compounds While the Sector Flattens

IDEXX’s stock has been in a drawdown since its November 2025 peak, but the latest quarter shows a company executing far better than the tape suggests. Revenue rose 10% as reported and 9% organically, while Strong recurring revenue growth drove the headline beat. The key divergence: U.S. same-store clinical visits fell an estimated 1.3% in Q2, yet CAG Diagnostics recurring revenue grew 10.3% organically. That premium is not a fluke—it reflects an expanding installed base, higher diagnostic utilization per visit, and a wave of new testing menus.

IDEXX U.S. CAG Diagnostics recurring revenue growth premium to U.S. clinical visits of approximately 1,100 basis points
Andrew Emerson, Chief Financial Officer · 2026-08-04

What’s changed versus prior quarters is how broad-based that premium has become. As CFO Andrew Emerson noted: “Revenue increased approximately 10% as reported and 9% organically, supported by over 10% organic growth in CAG Diagnostics recurring revenues, with double-digit gains in both the U.S. and international regions.” — Andrew Emerson, Chief Financial Officer · 2026-08-04 The growth comes even as clinical visit decline persists, a theme management has flagged for several quarters. But the mix is shifting: pets aged 5+ are now contributing positively to both wellness and non-wellness visits, and the company is leaning into that demographic tailwind.

inVue FNA: A Platform Within a Platform

FNA on inVue Dx is the most tangible new growth lever. Management reiterated its full-year placement target of 5,500 units, with 2,700 placed in H1. The controlled launch is progressing as planned, and the team is now broadening the rollout ahead of full availability by year-end. President and CEO Mike Erickson, on his first earnings call in the role, emphasized the extensibility of the platform: “Today, fewer than 10% of lumps and bumps ever get evaluated, largely due to the cost and workflow complexity of glass slides.” — Michael Erickson, President and Chief Executive Officer · 2026-08-04 That headroom is exactly what makes inVue FNA an incremental revenue driver. Erickson later added: “We're seeing early indications that the slide-free workflow, real-time results and affordable pricing of inVue Dx FNA are associated with an increased number of masses evaluated.” — Michael Erickson, President and Chief Executive Officer · 2026-08-04 Equally important, inVue’s consumables are tracking within the $3,500–$5,500 per instrument range, and each new application—blood morphology, ear cytology, and now FNA—expands the recurring revenue per placement. That aligns with the broader Catalyst menu strategy: adding SDMA to the Catalyst CLIPs, expanding Fecal Dx to include taeniid tapeworm, and preparing the Cancer Dx panel to add mast cell tumor detection. The latter is a direct sequel to the competitive lab traction—over 20% of Cancer Dx orders now come from practices using a competitor’s reference lab—a strong sign that innovation is pulling in new customers.

International Execution and Disciplined Investment

International CAG Diagnostics recurring revenue grew nearly 12% organically, sustaining double-digit gains. The company is investing in four additional international countries and targeted U.S. additions, a direct continuation of the playbook that has been yielding volume gains across regions. Erickson framed it as a long-term opportunity: “We're just really excited about the opportunity internationally. We know that there's a lot of headroom to grow placements, utilization to develop the sector for diagnostics, particularly around wellness.” — Jonathan Block, Analyst · 2026-08-04 Those incremental investments are expected to be partially offset by productivity, but the company maintains its confidence in the second-half outlook. On the margin side, IDEXX delivered 110bps of comparable operating margin expansion, with gross margins up 120bps to 64%. The long-run fundamentals are consistent: Total revenue reached $1.1B in the April quarter, up 14% y/y, and operating margin has stayed above 30% for eight of the last ten quarters. The company also raised its free cash flow conversion outlook to 90–100% of net income, a meaningful step up, and repurchased $693M of stock year-to-date.

The Road Ahead: Investor Day and a Raised Bar

The full-year outlook now implies organic CAG Dx recurring growth of 9.5–10.7%, up 40bps at midpoint from prior guidance. That revision comes despite the assumption that U.S. clinical visits will remain down ~1.5% in H2. The confidence rests on continued innovation cadence—Cancer Dx becoming a multi-cancer panel, FNA broadening, and software/imaging momentum—plus the durability of the installed base. As Andrew Emerson summarized: “We have a number of continued innovations that I think will support the back half and we maintain high customer loyalty levels in the high 90s really across our modalities.” — Andrew Emerson, Chief Financial Officer · 2026-08-04 Investors will get a deeper look at the multi-year algorithm at the Investor Day on August 13. For now, the story is straightforward: IDEXX is outgrowing its end-market by a wide margin, and the innovation pipeline shows no sign of slowing. The recent 90-day tape has been flat, but the fundamentals continue to warrant a premium multiple. As the company noted, the routine wellness visit still presents massive headroom—only ~1 in 10 U.S. wellness visits include bloodwork (blood work). That is the structural tailwind that keeps the premium intact.